The evidence for the clinical efficacy of tocilizumab in the therapy of RA suggested that effective suppression of IL-6-induced JAK/STAT activation was likely the operative mechanism responsible for its clinical effectiveness [17]. Here, SOAT1 is linked to rheumatoid arthritis.